A Look Into Healthcare Sector Value Stocks
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks
了解價值股
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
傳統上，價值股是根據市場上投資者如何估值該公司的未來增長前景來定義的。低市盈率倍數是表明公司被低估的良好基礎指標，很可能被貼上價值股的標籤。
The following stocks are considered to be notable value stocks in the healthcare sector:
以下股票被認爲是醫療保健領域值得注意的價值股票：
- Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 0.84
- Procaps Gr (NASDAQ:PROC) - P/E: 6.16
- InMode (NASDAQ:INMD) - P/E: 9.55
- Alkermes (NASDAQ:ALKS) - P/E: 9.56
- Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 7.97
- 基奧拉制藥（納斯達克股票代碼：KPRX）——市盈率：0.84
- Procaps Gr（納斯達克股票代碼：PROC）——市盈率：6.16
- InMode（納斯達克股票代碼：INMD）——市盈率：9.55
- Alkermes（納斯達克股票代碼：ALKS）——市盈率：9.56
- 錫羅斯製藥公司（納斯達克股票代碼：SYRS）——市盈率：7.97
Kiora Pharmaceuticals saw a decrease in earnings per share from -0.79 in Q2 to $-0.89 now. Procaps Gr saw a decrease in earnings per share from 0.27 in Q2 to $0.08 now. Most recently, InMode reported earnings per share at $0.71, whereas in Q3 earnings per share sat at $0.61. Alkermes's earnings per share for Q4 sits at $0.48, whereas in Q3, they were at 0.64. This quarter, Syros Pharmaceuticals experienced a decrease in earnings per share, which was $-1.3 in Q2 and is now $-1.43.
Kiora Pharmicals的每股收益從第二季度的-0.79美元下降至現在的-0.89美元。Procaps Gr的每股收益從第二季度的0.27美元下降至現在的0.08美元。最近，InMode公佈的每股收益爲0.71美元，而第三季度的每股收益爲0.61美元。Alkermes第四季度的每股收益爲0.48美元，而第三季度的每股收益爲0.64美元。本季度，Syros Pharmicals的每股收益有所下降，第二季度爲-1.3美元，目前爲-1.43美元。
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
意義：價值股可能需要一些時間才能從其被低估的位置中反彈。投資價值股的風險在於，這種出現可能永遠無法實現。